No CrossRef data available.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Published online by Cambridge University Press: 15 April 2020
The genetic determinism with such mental illnesses as schizophrenia has been insufficiently studied.
The aim of our study was to analyze the association of Val66Met polymorphism (Val allele and Met) for the brain-derived neurotrophic factor gene (BDNF gene) with the efficiency of therapy in patients with schizophrenia.
Were examined 142 patients with paranoid schizophrenia. All patients received different versions of antipsychotic pharmacotherapy.
Was found that the presence of Met allele genotype for the studied BDNF gene polymorphism determines a tendency to a more malignant clinical course with resistance to antipsychotic treatment in patients with paranoid schizophrenia. The results of molecular genetic analysis of schizophrenia will lead to better treatment this disorder and may be used in medical and genetic counseling.
You have
Access
Comments
No Comments have been published for this article.